Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00675428 · BASELINE

Baseline characteristics

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma · Source last updated 2014-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      3
    3. group Id
      BG002
      value
      6
    units
    Participants
groups
  1. description
    Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
    id
    BG000
    title
    Natalizumab 300 mg
  2. description
    Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
    id
    BG001
    title
    Natalizumab 450 mg
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          57
          upper Limit
          75
          value
          67.0
        2. group Id
          BG001
          lower Limit
          50
          upper Limit
          75
          value
          68.0
        3. group Id
          BG002
          lower Limit
          50
          upper Limit
          75
          value
          67.5
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          3
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          2
        3. group Id
          BG002
          value
          3
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      3
    3. group Id
      BG002
      value
      6
    units
    Participants
groups
  1. description
    Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
    id
    BG000
    title
    Natalizumab 300 mg
  2. description
    Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
    id
    BG001
    title
    Natalizumab 450 mg
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          57
          upper Limit
          75
          value
          67.0
        2. group Id
          BG001
          lower Limit
          50
          upper Limit
          75
          value
          68.0
        3. group Id
          BG002
          lower Limit
          50
          upper Limit
          75
          value
          67.5
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          3
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          2
        3. group Id
          BG002
          value
          3
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice